Children With Cancer UK grant
30 November 2017
The aim of the project is to offer a better treatment to children with brain tumours in the future.
A Children With Cancer UK grant has been awarded to Dr Beth Coyle (PI) and Dr Ali Bienemann (co-applicant). A total of £48,651 will go towards supporting a project entitled Convection enhanced delivery of N3-propargyl, a novel analogue of temozolomide.
TMZ is a DNA alkylating agent, activity of which depends on the absence of direct repair by O6-methylguanine-DNA-methyltransferase (MGMT) and proficient mismatch repair (MMR). We have developed and demonstrated the ability of a novel temozolomide analogue (N3-propargyl) to circumvent MGMT in a non-mutagenic manner in vitro across a broad range of MGMT expressing adult (glioblastomas) and paediatric brain tumours (pHGG, diffuse intrinsic pontine glioma (DIPG), ependymoma and medulloblastoma. This project gives a perfect opportunity to match a novel potent drug (N3-propargyl) to a delivery system ideally suited to its activation profile in children’s high grade gliomas. By focussing our initial studies on pHGG and DIPG we will be targeting tumour types where there is the greatest need for effective chemotherapy.